ScripKronos Bio Inc. left most of its employees with little to be thankful for on 27 November when it announced a day before the Thanksgiving holiday in the US that in addition to CEO Norbert Bischofberger
ScripRetooling a company to focus on a single asset is a high-risk strategy, and one that is generally taken when few other choices present themselves. Having taken this step last year, Kezar Life Science
ScripRoche Holding AG could be third to market in the autoimmune disease lupus nephritis after claiming a topline hit in the pivotal REGENCY trial. More people responded to the anti-CD20 antibody in the P
ScripImperative And Execution At the end of May 2024, the NASDAQ Biotech Index (NBI) fell into negative territory both in the year to date and compared with the previous 12 months. This was despite the imp